ESSA’s lead clinical candidate, EPI-7386, is a first-in-class N-terminal domain androgen receptor inhibitor in development for the treatment of androgen receptor (AR)-driven prostate cancer. ESSA believes that by inhibiting both the N-terminal and the ligand-binding domains of AR, greater suppression of androgen biology may be possible potentially delaying the emergence of drug resistance. We are investigating EPI-7386 in combination trials in patients with prostate cancer. By targeting the AR through two independent pathways, combination therapies have the potential to improve the treatment of prostate cancer and provide a new standard of care for both early and advanced disease.
For more information, please visit clinicaltrials.gov.
We are partnering with pharmaceutical companies who have developed second generation antiandrogens that are approved for the treatment of prostate cancer. ESSA is currently collaborating with Janssen Research & Development, LLC (Janssen), Astellas Pharma Inc. (Astellas), and Bayer to evaluate EPI-7386 in combination with these companies’ antiandrogen treatments in Phase 1/2 trials.
